Leflunomide Pharmacology episode artwork

EPISODE · Feb 25, 2021 · 12 MIN

Leflunomide Pharmacology

from Real Life Pharmacology - Pharmacology Education for Health Care Professionals

On this episode, I discuss leflunomide pharmacology. It is classified as a DMARD and is primarily used in rheumatoid arthritis. Leflunomide carries a boxed warning for hepatoxicity. LFTs must be monitored with its use. Leflunomide can inhibit CYP2C8 which plays an important role in pioglitazone metabolism. Concentrations of pioglitazone can go up on account of this interaction. TB screening should be done prior to beginning the immunosuppressant leflunomide. I discuss important drug interactions on the podcast, be sure to check out my latest project which is a 200+ page book on managing drug interactions in primary care. Be sure to check out our free Top 200 study guide – a 31 page PDF that is yours for FREE!

Episode metadata supplied by the publisher feed · Published Feb 25, 2021

Embed this episode

NOW PLAYING

Leflunomide Pharmacology

0:00 12:05

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Real Life Pharmacology - Pharmacology Education for Health Care Professionals?

This episode is 12 minutes long.

When was this Real Life Pharmacology - Pharmacology Education for Health Care Professionals episode published?

This episode was published on February 25, 2021.

Can I download this Real Life Pharmacology - Pharmacology Education for Health Care Professionals episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!